Our researcher is completing a pilot study of a drug that impacts basic changes in genetic structure for a rare, but always fatal disease. She is wondering if she is on the right track, particularly regarding the dosage level. She is not yet ready for clinical trials and a double blind study but feels both hope and pressure because the absence of effective treatments and because of the seriousness of the problem. Gene therapy researchers have had remarkable breakthroughs, along with several dead-ends. She is looking for advice about an appropriate Alpha level to determine trends in the data. Of .25, .10, .05, .01, or .001, which Alpha level would you suggest for this preliminary pilot study? Explain your rationale for the significance level you recommend.